Lexicon Pharmaceuticals (LXRX) Accumulated Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Accumulated Expenses for 17 consecutive years, with $6.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 46.69% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (down 46.69% YoY), while the FY2025 annual figure was $13.2 million, down 56.68% from the prior year.
• Accumulated Expenses eased to $6.9 million in Q1 2026 per LXRX's latest filing, from $13.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $30.4 million in Q4 2024 and bottomed at $6.9 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $14.4 million across 5 years, with a median of $13.2 million in 2025.
• Annual changes were most pronounced in 2022 — Accumulated Expenses sank 57.23% — and 2023, when it surged 124.27%.
• Lexicon Pharmaceuticals' Accumulated Expenses stood at $12.8 million in 2022, then surged by 34.28% to $17.2 million in 2023, then soared by 77.46% to $30.4 million in 2024, then slumped by 56.68% to $13.2 million in 2025, then tumbled by 47.67% to $6.9 million in 2026.
• Business Quant data shows LXRX's Accumulated Expenses at $6.9 million in Q1 2026, $13.2 million in Q4 2025, and $13.6 million in Q3 2025.